|
Management / Directors
Dr. Allen (Alexander) Krantz, President, CEO
and Director
Allen Krantz, the founder of Advanced Proteome Therapeutics , has had an extensive
career in academia and industry. From 1968 to 1974, he was a member of the Faculty
of Chemistry at the State University of New York at Stony Brook and from 1974
to 1981 he held appointments in both the Department of Chemistry and the Department
of Pharmacological Sciences in the Medical School in that same institution. From
1981 to 1992, Dr. Krantz was Director of Research at Syntex Research Canada and
held Adjunct Professorships during this period at the Universities of Toronto
and Guelph. In 1992, Dr. Krantz was appointed Vice-President of Research at Syntex
and held the title of Distinguished Scientist from 1993-1994. From 1994 to 1997,
Dr. Krantz served as Executive Vice President of Research at RedCell, Inc., the
forerunner of ConjuChem, (TSX: CJC), and served as the Directeur Scientifique
of the European office in France during the same period. Dr. Krantz was responsible
for transforming the company's program to a practical focal point on human serum
albumin as a carrier of drugs. He is also a Founder, and served as the inaugural
President of Pharmena North America Incorporated, a privately held, biotechnology
company. Dr. Krantz obtained his Masters of Science and Ph.D. degrees from Yale
University.
Dr. Gary Hayes, MD - Director
Dr Hayes graduated from the University of Manitoba in 1978. He
has 27 years in clinical Family Practice, and has been a medical
advisor to numerous companies and sports teams that utilize his
extensive knowledge of therapeutics. Dr Hayes has also been active
as a Director of several publicly traded companies.
Jean Bellin, Director
Jean Bellin has more than 25 years experience in
the pharmaceutical industry, including sales, marketing, business
development, mergers and acquisitions, and general management – both
domestic and international. He began his pharmaceutical
industry career with 12 years at Eli Lilly & Company, holding
positions in sales, marketing and general management in Brazil,
the US, the Scandinavian countries and Italy. He then
founded and served as Managing Director of DuPont Pharma Italy. In
1993, Mr. Bellin became the head of the international division
of UCB, a $2 billion publicly traded, biopharmaceutical group
based in Brussels, Belgium. There he managed the pharmaceutical
subsidiaries in the US, Canada, South America, Japan, China
and Southeast Asia. Later he managed the osteohealth
and animal health divisions of Sankyo Pharmaceuticals Company
Ltd., then the second largest pharmaceutical company in Japan.
He was also previously the CEO of Mountain View Pharmaceuticals
Inc., a California-based biopharmaceutical company where the
PEGylation of therapeutic proteins was a major focus. He is
currently the President of Metagenics, a leading manufacturer
and distributor of medical foods and nutraceuticals. Mr. Bellin
received his bachelor’s degree in Economic, Political
and Social Sciences from the Universitaires Saint Louis in
Brussels and a license in applied economic sciences from the
Catholique de Louvain in Belgium.
|
